Zydus Cadila gets USFDA nod to Fluphenazine Hydrochloride Tablets

Written by Ruchika Sharma Published On 2021-05-30T09:30:31+05:30 | Updated On 30 May 2021 9:30 AM IST

Zydus Cadila gets USFDA nod to Fluphenazine Hydrochloride Tablets

Ahmedabad: Drugmaker, Zydus Cadila, has recently announced that the company has received final approval from the USFDA to market Fluphenazine Hydrochloride Tablets in the strengths of 1 mg, 2.5 mg, 5 mg, and 10 mg (US RLD: Prolixin Tablets).

This medication is used to treat symptoms of a certain type of mental/mood condition (schizophrenia).

Fluphenazine belongs to a class of medications called phenothiazines and is also referred to as a neuroleptic.

The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 318 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is a global pharmaceutical company headquartered in Ahmedabad, India.

The company discovers, develops, manufactures, and markets a broad range of healthcare therapies.

Read also: Zydus Cadila seeks DCGI nod for clinical trials of monoclonal antibodies cocktail that neutralises COVID infection

zydus cadilazydus cadila newsusfdaschizophreniafluphenazine hydrochloride tablets

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751